Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma.

[1]  A. Belldegrun,et al.  Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. , 2013, The Journal of urology.

[2]  M. Saito,et al.  The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma. , 2013, Urologic oncology.

[3]  D. Amadori,et al.  Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma , 2013, British Journal of Cancer.

[4]  M. Wirth,et al.  Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study , 2013, BJU international.

[5]  K. Pummer,et al.  Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients , 2013, British Journal of Cancer.

[6]  E. Plimack,et al.  Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. , 2013, The Journal of urology.

[7]  R. Montironi,et al.  VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib , 2012, British Journal of Cancer.

[8]  F. Montorsi,et al.  A review of integrated staging systems for renal cell carcinoma. , 2012, European urology.

[9]  J. Nakashima,et al.  Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. , 2012, The Journal of urology.

[10]  R. Uzzo,et al.  Utility of the R.E.N.A.L. nephrometry scoring system in objectifying treatment decision-making of the enhancing renal mass. , 2011, Urology.

[11]  W. Gregory,et al.  Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein , 2010, British Journal of Cancer.

[12]  J. Nakashima,et al.  Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. , 2010, The Journal of urology.

[13]  A. Belldegrun,et al.  Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma. , 2010, The Journal of urology.

[14]  R. Uzzo,et al.  Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Peter A Pinto,et al.  The clinical implications of the genetics of renal cell carcinoma. , 2009, Urologic oncology.

[17]  D. McMillan,et al.  Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse‐free and cancer‐specific survival in patients undergoing potentially curative resection for renal cancer , 2008, BJU international.

[18]  Walter Artibani,et al.  Grading systems in renal cell carcinoma. , 2007, The Journal of urology.

[19]  P. Russo,et al.  Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Cheville,et al.  Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. , 2006, Urology.

[21]  J. Blay,et al.  Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Horita,et al.  High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. , 2004, The Journal of urology.

[23]  A. Elhan,et al.  Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. , 2004, Urology.

[24]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[25]  B. Delahunt,et al.  Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[26]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[27]  J. Cheville,et al.  Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma. , 2012, The Journal of urology.

[28]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[30]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .

[31]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[32]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.